Soleno Therapeutics prices public offering at $85 per share

Soleno Therapeutics (SLNO) has priced an underwritten public offering of 2,352,941 shares at $85.00, expecting to raise approximately $200 million to fund the commercialization of its recently FDA-approved Prader-Willi syndrome drug, VYKAT XR, and other strategic initiatives. The offering follows the stock's impressive 105.84% return over the past year and coincides with strong preliminary Q2 VYKAT XR revenue of $31-$33 million. Analysts from Stifel and Piper Sandler have reiterated Buy/Overweight ratings with price targets up to $145, citing robust demand, high physician adoption, and significant sales potential for VYKAT XR, despite the company not yet being profitable but maintaining strong liquidity.

Analysis

Soleno Therapeutics (SLNO) is strategically capitalizing on its recent operational success and strong market momentum by pricing a public offering of approximately $200 million at $85.00 per share. This action follows a 105.84% stock price appreciation over the past year and the recent FDA approval of its key drug, VYKAT XR, for Prader-Willi syndrome. The core driver for the company's positive outlook is the drug's robust initial launch, with preliminary second-quarter revenues projected between $31 million and $33 million. This commercial traction is supported by strong physician adoption, with a Stifel survey indicating 70% of relevant doctors are prescribing the treatment, and favorable early reimbursement dynamics. Despite not yet being profitable, the company maintains a strong liquidity position, evidenced by a current ratio of 19.64 and a pre-offering cash balance of $293.8 million. Analyst sentiment is highly bullish, with Piper Sandler and Stifel reiterating Overweight/Buy ratings and setting price targets of $145 and $115 respectively, well above the offering price, based on VYKAT XR's potential to achieve sales exceeding $2 billion.

Key Decisions for Investors

• Given the strong initial sales of VYKAT XR and bullish analyst price targets significantly above the $85 offering price, investors may view this capital raise as a strategic entry or accumulation point for exposure to a high-growth biotech story.
• Investors should closely monitor upcoming earnings reports to verify the sustainability of VYKAT XR's revenue trajectory and track progress on European regulatory activities, as these are the primary catalysts underpinning the current valuation.
• While the outlook is positive, the dilutive impact of the share offering and the company's pre-profitability status represent key risks; therefore, it is prudent to assess the company's cash burn rate against its commercialization expenses in the coming quarters.